Dermatophytic Onychomycosis Treatment Market, By Product Type (Tablets(Rx, OTC)Mail Paints(Rx, OTC)), By Treatment (Oral, Topical), By End User (Hospitals, Clinics, Independent Pharmacies, Mail Order Pharmacies, Drug Stores), and by Regions (North America

Dermatophytic Onychomycosis Treatment Market, By Product Type (Tablets(Rx, OTC)Mail Paints(Rx, OTC)), By Treatment (Oral, Topical), By End User (Hospitals, Clinics, Independent Pharmacies, Mail Order Pharmacies, Drug Stores), and by Regions (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Nail onychomycosis is a fungal infection is caused by a trichophyton rubrum, trichophyton mentagrophytes, and in some cases it is caused by yeasts and molds. The major factors responsible for nail onchomycosis infection is increased exposure to worm and moist environment which leads to perfect condition for fungus to grow and proliferate. The major symptoms of onychomycosis comprises of white and yellow spots under the nail leading to discoloration, nail thickening, and formation of crumbling edges on the nail.
Key features of the study:
This report provides in-depth analysis of the global dermatophytic onychomycosis treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatophytic onychomycosis treatment market
Detailed Segmentation:
Dermatophytic Onychomycosis Treatment Market, By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
Dermatophytic Onychomycosis Treatment Market, By Treatment:
Oral
Topical
Dermatophytic Onychomycosis Treatment Market, By End User:
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
Dermatophytic Onychomycosis Treatment Market, By Region:
North America
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
U.S.
Canada
Latin America
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Tablets
Rx
OTC
Mail Paints
Rx
OTC
By Treatment
Oral
Topical
By End User
Hospitals
Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Valeant Pharmaceuticals International Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Galderma S.A.
Novartis AG
Pfizer Inc.
Moberg Pharma AB
Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
Anacor Pharmaceuticals, Inc.
NovaQuest Capital Management, L.L.C.
Novan, Inc.
“*” marked represents similar segmentation in other categories in the respective section.